Brokerages Anticipate CareTrust REIT, Inc. (NASDAQ:CTRE) Will Announce Quarterly Sales of $48.33 Million

Brokerages expect CareTrust REIT, Inc. (NASDAQ:CTREGet Rating) to report $48.33 million in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for CareTrust REIT’s earnings. The highest sales estimate is $50.00 million and the lowest is $45.80 million. CareTrust REIT posted sales of $45.75 million in the same quarter last year, which would indicate a positive year over year growth rate of 5.6%. The firm is scheduled to issue its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that CareTrust REIT will report full-year sales of $193.91 million for the current year, with estimates ranging from $185.00 million to $198.60 million. For the next fiscal year, analysts anticipate that the company will report sales of $199.40 million, with estimates ranging from $189.40 million to $207.60 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that follow CareTrust REIT.

CareTrust REIT (NASDAQ:CTREGet Rating) last posted its quarterly earnings data on Tuesday, February 15th. The real estate investment trust reported $0.19 EPS for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.06). CareTrust REIT had a net margin of 37.42% and a return on equity of 7.81%. During the same period in the previous year, the firm posted $0.36 EPS.

A number of analysts have commented on CTRE shares. Barclays reduced their price target on CareTrust REIT from $26.00 to $22.00 in a research report on Tuesday, February 22nd. Credit Suisse Group began coverage on CareTrust REIT in a research report on Tuesday, February 1st. They issued a “neutral” rating and a $22.00 price target for the company. BMO Capital Markets cut CareTrust REIT from an “outperform” rating to a “market perform” rating and set a $20.00 target price for the company. in a research report on Friday, March 11th. Raymond James cut their target price on CareTrust REIT from $27.00 to $23.00 and set a “strong-buy” rating for the company in a research report on Friday, March 18th. Finally, TheStreet cut CareTrust REIT from a “b” rating to a “c+” rating in a research report on Monday, February 14th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, one has issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $22.14.

CTRE traded down $0.13 during midday trading on Wednesday, reaching $17.52. The company had a trading volume of 653,596 shares, compared to its average volume of 725,873. The company has a quick ratio of 0.88, a current ratio of 0.88 and a debt-to-equity ratio of 0.74. The business has a 50-day moving average of $18.42 and a two-hundred day moving average of $20.32. The company has a market cap of $1.70 billion, a P/E ratio of 23.68 and a beta of 1.16. CareTrust REIT has a 1 year low of $16.86 and a 1 year high of $24.85.

The company also recently declared a quarterly dividend, which was paid on Friday, April 15th. Investors of record on Thursday, March 31st were paid a dividend of $0.275 per share. The ex-dividend date was Wednesday, March 30th. This is a positive change from CareTrust REIT’s previous quarterly dividend of $0.27. This represents a $1.10 dividend on an annualized basis and a yield of 6.28%. CareTrust REIT’s dividend payout ratio is presently 148.65%.

A number of institutional investors have recently made changes to their positions in the stock. First Trust Advisors LP lifted its stake in shares of CareTrust REIT by 37.7% in the 1st quarter. First Trust Advisors LP now owns 171,743 shares of the real estate investment trust’s stock valued at $4,029,000 after purchasing an additional 47,027 shares during the last quarter. Morgan Stanley lifted its stake in shares of CareTrust REIT by 74.4% in the 2nd quarter. Morgan Stanley now owns 720,863 shares of the real estate investment trust’s stock valued at $16,746,000 after purchasing an additional 307,505 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. lifted its stake in shares of CareTrust REIT by 0.7% in the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 136,427 shares of the real estate investment trust’s stock valued at $2,772,000 after purchasing an additional 971 shares during the last quarter. Meritage Portfolio Management lifted its stake in shares of CareTrust REIT by 30.5% in the 3rd quarter. Meritage Portfolio Management now owns 155,026 shares of the real estate investment trust’s stock valued at $3,150,000 after purchasing an additional 36,212 shares during the last quarter. Finally, Westpac Banking Corp lifted its stake in shares of CareTrust REIT by 17.0% in the 3rd quarter. Westpac Banking Corp now owns 291,811 shares of the real estate investment trust’s stock valued at $5,930,000 after purchasing an additional 42,378 shares during the last quarter. 85.72% of the stock is owned by institutional investors.

CareTrust REIT Company Profile (Get Rating)

CareTrust REIT, Inc is a self-administered, publicly-traded real estate investment trust engaged in the ownership, acquisition, development and leasing of skilled nursing, seniors housing and other healthcare-related properties. With a nationwide portfolio of long-term net-leased properties, and a growing portfolio of quality operators leasing them, CareTrust REIT is pursuing both external and organic growth opportunities across the United States.

Further Reading

Get a free copy of the Zacks research report on CareTrust REIT (CTRE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for CareTrust REIT (NASDAQ:CTRE)

Receive News & Ratings for CareTrust REIT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareTrust REIT and related companies with MarketBeat.com's FREE daily email newsletter.